Read by QxMD icon Read


Claudio I Perez, Felipe Mellado, Alex Jones, Ricardo Colvin
PURPOSE OF THE STUDY: The purpose of the study was to report and evaluate outcomes of trabeculectomy with use of a subconjunctival biodegradable collagen matrix implant. PATIENTS AND METHODS: Retrospective review of trabeculectomy with Ologen implant of 65 eyes of 58 patients by the same surgeon from October, 2011 to October, 2014. Exclusion criteria were <6 months of follow-up after surgery, and uveitic or neovascular glaucoma. Demographic characteristics of the study population, visual acuity, intraocular pressure (IOP), glaucoma medications, bleb characteristics, and early and late postoperative complications were recorded...
January 2017: Journal of Glaucoma
Eman M Elhefney, Hossam T Al-Sharkawy, Hanem M Kishk, Hossam Abouelkheir
PURPOSE: To evaluate the preliminary results of biodegradable collagen matrix implant (Ologen) designed to improve outcome in patients with infantile glaucoma undergoing combined trabeculotomy and trabeculectomy. METHODS: A biodegradable collagen matrix (OculusGen) was placed in the subconjunctival space, partially over the scleral flap and the sclera in 20 eyes of 11 patients with infantile glaucoma who underwent combined trabeculotomy and trabeculectomy. Patients were examined preoperatively and on the first postoperative day with multiple postoperative follow-up visits within 12 months after surgery...
September 7, 2016: European Journal of Ophthalmology
Dewang Angmo, Meenakshi Wadhwani, Ashish Dutt Upadhyay, Shreyas Temkar, Tanuj Dada
PURPOSE: To evaluate the efficacy and safety of trabeculectomy with combined subconjunctival and subscleral ologen implant in eyes with advanced glaucomatous optic neuropathy. DESIGN: This is a retrospective, noncomparative case series. METHODS: Twenty seven eyes of 23 patients with advanced primary glaucoma who underwent fornix-based trabeculectomy with insertion of ologen both subsclerally and subconjunctivally along with low dose Mitomycin-C (0...
January 2017: Journal of Glaucoma
Kang-Hyo Park, Joon-Young Kim, Seoung-Woo Choo, Hun-Young Yoon, Soon-Wuk Jeong
An Ahmed valve implantation with an Ologen(®) Collagen Matrix (Ologen(®) CM, Aeon Astron, Leiden, the Netherlands) was performed for the treatment of uncontrolled glaucoma in a cat. This cat was a 5-year-old castrated Russian Blue male with a 12-week history of conjunctival hyperemia and mydriasis of the left eye. During the ophthalmic examination, the intraocular pressure (IOP) oculus sinister (OS) was 52 mmHg, and a narrow iridocorneal angle (ICA) was detected by gonioscopy. Medical treatment with Cosopt(®) (2% dorzolamide and 0...
August 19, 2016: Veterinary Ophthalmology
H M A El-Saied, M A S E Abdelhakim
PurposeWe aimed to assess the IOP-lowering effect of trabeculectomy with ologen in refractory secondary glaucoma following failed trabeculectomy with mitomycin C (MMC), and to compare its surgical outcome between open angle (SOAG) and angle closure (SACG) cases.MethodsThis is a prospective interventional comparative study conducted on 40 eyes (40 patients) with medically uncontrolled secondary glaucoma. Patients were divided into group A: 18 eyes (18 patients) with SOAG, and group B: 22 eyes (22 patients) with SACG...
August 2016: Eye
Salvatore Cillino, Alessandra Casuccio, Francesco Di Pace, Carlo Cagini, Lucia Lee Ferraro, Giovanni Cillino
BACKGROUND: Clinical studies comparing trabeculectomy augmented with Ologen implant (OLO) versus trabeculectomy plus mitomycin-C (MMC) show contradictory results. To obtain long-term data, we report an extended 5-year follow-up trial evaluating the safety and efficacy of OLO as adjuvant compared to low-dosage MMC in trabeculectomy. METHODS: Forty glaucoma patients (40 eyes) assigned to trabeculectomy with MMC or Ologen. PRIMARY OUTCOME: target IOP at ≤21, ≤17 and ≤15 mmHg; complete and qualified success endpoint rates...
2016: BMC Ophthalmology
T H van Essen, L van Zijl, T Possemiers, A A Mulder, S J Zwart, C-H Chou, C C Lin, H J Lai, G P M Luyten, M J Tassignon, N Zakaria, A El Ghalbzouri, M J Jager
PURPOSE: To determine whether a fish scale-derived collagen matrix (FSCM) meets the basic criteria to serve as an artificial cornea, as determined with in vitro and in vivo tests. METHODS: Primary corneal epithelial and stromal cells were obtained from human donor corneas and used to examine the (in)direct cytotoxicity effects of the scaffold. Cytotoxicity was assessed by an MTT assay, while cellular proliferation, corneal cell phenotype and adhesion markers were assessed using an EdU-assay and immunofluorescence...
March 2016: Biomaterials
Xue Wang, Rabeea Khan, Anne Coleman
BACKGROUND: Glaucoma is an optic neuropathy that leads to vision loss and blindness. It is the second most common cause of irreversible blindness worldwide. The main treatment for glaucoma aims to reduce intraocular pressure (IOP) in order to slow or prevent further vision loss. IOP can be lowered with medications, and laser or incisional surgeries. Trabeculectomy is the most common incisional surgical procedure to treat glaucoma. Device-modified trabeculectomy is intended to improve drainage of the aqueous humor to lower IOP...
December 1, 2015: Cochrane Database of Systematic Reviews
Fei Yuan, Lei Li, Xiuping Chen, Xiang Yan, Liyang Wang
Purpose. To evaluate the effectiveness and safety of the Ologen as an aid for trabeculectomy performed for primary open-angle glaucoma compared with mitomycin C. Methods. In this prospective, randomized, parallel assignment, comparative study, 31 eyes of 21 primary open-angle glaucoma patients were allocated for trabeculectomy with the Ologen implant; another 32 eyes of 23 patients were treated with trabeculectomy augmented with mitomycin C. The patients were followed up for 5 years and evaluated for intraocular pressure, rate of success, status of the bleb, and adverse events...
2015: Journal of Ophthalmology
Tanuj Dada, Reetika Sharma, Gautam Sinha, Dewang Angmo, Shreyas Temkar
PURPOSE: To describe a novel technique of trabeculectomy combined with cyclodialysis and Ologen implantation at 3 sites in cases with high risk for failure of trabeculectomy. METHODS: Six eyes of 6 patients who had high risk for failure of trabeculectomy underwent cyclodialysis-augmented trabeculectomy with Ologen implantation at 3 sites using the described technique. RESULTS: All the eyes achieved target intraocular pressure, which was maintained until 1 year of follow-up...
January 2016: European Journal of Ophthalmology
Qingshan Ji, Bing Qi, Lian Liu, Xiaoling Guo, Jingxiang Zhong
PURPOSE: To assess the efficacy and safety of trabeculectomy with Ologen implant versus trabeculectomy with mitomycin C (MMC) for treatment of glaucoma. PATIENTS AND METHODS: Medline, EMBASE, Web of Science, Cochrane Central Register of Controlled Trials, and Google Scholar were searched for relevant randomized controlled trials. The outcome measures of efficacy were intraocular pressure and glaucoma medications reductions, and success rate. Safety estimates were measured by relative ratio for complications...
June 2015: Journal of Glaucoma
O K Radhakrishnan, Kishore Pahuja, Khevna Patel, Sunaina Chandna
We report an unusual case of Axenfeld-Rieger Syndrome with secondary glaucoma managed with Ologen(®) implant. A 35-year-old male presented with complaints of decreased vision in both eyes of 22 years duration. His best corrected visual acuity (BCVA) was no perception of light in right eye and 20/30 in left eye. Gonioscopy revealed anterior insertion of iris into trabecular meshwork, prominent iris processes and broad-based synechiae with prominent Schwalbe's line along the angle circumference with cord-like structures taking its origin at the level of Schwalbe's line in both eyes...
May 2014: Oman Journal of Ophthalmology
Shivali A Menda, Eugene A Lowry, Travis C Porco, Robert L Stamper, Michel R Rubin, Ying Han
To compare the complication rate and effectiveness of mitomycin C (MMC), Ologen alone, and Ologen with 5-fluorouracil (5-FU) as adjunctives with Ex-PRESS mini shunt for medically uncontrolled glaucoma. Retrospective comparative study of 59 Ex-PRESS mini shunt trabeculectomy operations coupled with Ologen implantation alone, transient MMC application or Ologen implantation with 5-FU as adjunctive treatment. Eight eyes (7 patients) received Ologen alone, 37 eyes (34 patients) received MMC, and 14 eyes (14 patients) received Ologen with 5-FU as adjunctive therapy...
June 2015: International Ophthalmology
Miao He, Wei Wang, Xiulan Zhang, Wenyong Huang
OBJECTIVE: To evaluate the application of the Ologen implant compared to mitomycin C (MMC) on the outcome of trabeculectomy and to examine the balance of risks and benefits. METHODS: A systematic literature search (Pubmed, Embase, the Cochrane Library, and the Chinese Biomedicine Database) was performed. Randomized controlled trials comparing the Ologen implant with MMC in trabeculectomy were selected. The efficacy measures were the weighted mean differences (WMDs) for the intraocular pressure reduction (IOPR), the reduction in glaucoma medications, and the relative risks (RRs) for success rates...
2014: PloS One
André Rosentreter, Stergiani Gaki, Claus Cursiefen, Thomas S Dietlein
PURPOSE: To assess the efficacy of trabeculectomy with a biodegradable Ologen™ implant (OLO) versus mitomycin C (MMC) in patients in a prospective randomized clinical trial. METHODS: In the MMC group (15 patients), trabeculectomy was performed according to standard protocols. In the OLO group (15 patients) after standard trabeculectomy, the implant was positioned on top of the scleral flap, and no MMC was applied. RESULTS: Mean preoperative intraocular pressure (IOP) levels (OLO: 28...
2014: Ophthalmologica. Journal International D'ophtalmologie
Matthew S Johnson, Steven R Sarkisian
PURPOSE: To compare outcomes between patients undergoing trabeculectomy with an Ex-PRESS mini glaucoma device using mitomycin-C (MMC) to those undergoing the same procedure using a subconjunctival collagen matrix implant (Ologen). MATERIALS AND METHODS: All patients underwent a trabeculectomy using an Ex-PRESS shunt. A total of 49 eyes of 37 patients received Ologen, and 50 eyes of 48 patients received MMC. Postoperative data were reviewed over 12 months. Outcomes included mean intraocular pressure (IOP), rate of success in achieving a target IOP (with and without antiglaucoma medications), number of medications used, and rates of complications/reoperations...
December 2014: Journal of Glaucoma
Sirisha Senthil, Harsha L Rao, Jonnadula G Babu, Anil K Mandal, Chandra Sekhar Garudadri
PURPOSE: To compare the safety and efficacy of trabeculectomy with Ologen implant vs. trabeculectomy with Mitomycin C (MMC). MATERIALS AND METHODS: In a prospective, randomized, pilot study, 39 eyes of 33 subjects with medically uncontrolled primary glaucoma, aged 18 years or above underwent trabeculectomy either with MMC (20 eyes) or with Ologen implant (19 eyes). The primary outcome measure was cumulative success probability, defined as complete if the intraocular pressure (IOP) was > 5 and ≤ 21 mm Hg without anti-glaucoma medications or additional surgery and qualified if an IOP was > 5 and ≤ 21 mm Hg with or without anti-glaucoma medications...
July 2013: Indian Journal of Ophthalmology
Arun Narayanaswamy, Shamira A Perera, Hla M Htoon, Sek-Tien Hoh, Steve K Seah, Tina T Wong, Tin Aung
BACKGROUND: To assess the efficacy and safety of collagen matrix implant (Ologen) in phacotrabeculectomy. DESIGN: Prospective, non-randomized, comparative study. PARTICIPANTS: Sixty-six Asian patients. METHODS: Thirty three consecutive patients underwent phacotrabeculectomy with Ologen implant and intraocular lens implantation, and 33 subjects recruited as controls underwent surgery with mitomycin C augmentation. MAIN OUTCOME MEASURES: The primary outcome measure was postoperative intraocular pressure at month 12...
August 2013: Clinical & Experimental Ophthalmology
Jung Kee Min, Chang Won Kee, Sae Woon Sohn, Hyun Joo Lee, Je Moon Woo, Jin Ho Yim
PURPOSE: To assess the surgical outcomes and wound healing reaction of a filtering bleb after trabeculectomy using mitomycin C-soaked biodegradable collagen matrix (ologen). METHODS: Thirty eyes, in which the intraocular pressure (IOP) could not be controlled within the proper range by medication or laser treatment, were targeted in this study. After trabeculectomy with mitomycin C (0.2 mg/mL, 0.1 mL)-soaked ologen, surgical outcomes were assessed by evaluating bleb morphology by the Moorfield bleb grading system, as well as internal reflectivity and wound healing response of the bleb using a slit lamp and ultrasound biomicroscopy...
August 2013: Journal of Glaucoma
Hatem M Marey, Sameh S Mandour, Amin F Ellakwa
PURPOSE: To compare the results of subscleral trabeculectomy (SST) augmented with mitomycin-C (MMC) versus Ologen™ implant regarding intraocular pressure (IOP) control and incidence of complications. METHODS: Sixty eyes of 60 patients, who planned to undergo SST, were divided into 2 groups. Group I eyes (included thirty eyes) were operated upon with SST augmented with intraoperative MMC. Group II eyes (included 30 eyes) were operated upon with SST using an Ologen implant...
April 2013: Journal of Ocular Pharmacology and Therapeutics
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"